
Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.

Your AI-Trained Oncology Knowledge Connection!


Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.

Sarah Donahue, MPH, NP, discusses her strategy for administering doxorubicin, cyclophosphamide, and antiemetics to manage nausea following trastuzumab deruxtecan therapy for patients with hormone receptor–positive breast cancer.

Fatigue and mouth sores are some of the common adverse effects associated with treatment using palbociclib or ribociclib, says Sarah Donahue, MPH, NP.

Treatment with CDK4/6 inhibitors does not appear to result in severe neutropenic fever compared with chemotherapy for breast cancer, according to Sarah Donahue, MPH, NP.